Maryam Mansoori1,2, Isa Abdi Rad3, Alireza Mirzaei4, Kevin J Tam5, Seyed Mohsen Hosseini6, Rahim Mahmodlu7, Fatemeh Mansouri8, Leili Saeednejad Zanjani1, Zahra Madjd1,2. 1. Iran University of Medical Sciences, Oncopathology Research Center, Tehran, Iran. 2. Iran University of Medical Sciences, Faculty of Advanced Technologies in Medicine, Department of Molecular Medicine, Tehran, Iran. 3. Urmia University of Medical Sciences, Cellular and Molecular Research Center, Urmia, Iran. 4. Iran University of Medical Sciences, Shafa Orthopedic Hospital, Bone and Joint Reconstruction Research Center, Tehran, Iran. 5. University of British Columbia, Vancouver Prostate Centre, Department of Urologic Sciences, Vancouver, Canada. 6. Omid specialty and subspecialty Hospital, Oncology and Radiotherapy Ward, Urmia, Iran. 7. Urmia University of Medical Sciences, Faculty of Medicine, Imam Khomeini Hospital, Department of Surgery, Urmia, Iran. 8. Urmia University of Medical Sciences, Faculty of Medicine, Department of Genetics and Immunology, Urmia, Iran.
Abstract
INTRODUCTION: Cancer stem cells (CSCs) are a theorized subset of cells within the tumor that is thought to drive disease recurrence and metastatic spread. The aim of this study is to investigate mRNA and protein levels of ganglioside GD2 synthase (GD2S), in breast cancer (BC) patients. METHODS: 65 PBMCs of preoperative BC patients without chemotherapy were compared to PBMCs after chemotherapy and controls. RESULTS: GD2S were significantly higher in BC patients after chemotherapy compared to pre-chemotherapy at both mRNA and protein. GD2S was higher in pre-chemotherapy blood samples compared to control samples. CONCLUSIONS: Higher expression of GD2S in BC samples compared to healthy control indicates the potential utility of GD2S as a marker of malignancy.
INTRODUCTION: Cancer stem cells (CSCs) are a theorized subset of cells within the tumor that is thought to drive disease recurrence and metastatic spread. The aim of this study is to investigate mRNA and protein levels of ganglioside GD2 synthase (GD2S), in breast cancer (BC) patients. METHODS: 65 PBMCs of preoperative BC patients without chemotherapy were compared to PBMCs after chemotherapy and controls. RESULTS: GD2S were significantly higher in BC patients after chemotherapy compared to pre-chemotherapy at both mRNA and protein. GD2S was higher in pre-chemotherapy blood samples compared to control samples. CONCLUSIONS: Higher expression of GD2S in BC samples compared to healthy control indicates the potential utility of GD2S as a marker of malignancy.
Entities:
Keywords:
Breast cancer; Cancer stem cell; Circulating cancer stem cell; ELISA; qRT-PCR
Authors: Marija Balic; Henry Lin; Lillian Young; Debra Hawes; Armando Giuliano; George McNamara; Ram H Datar; Richard J Cote Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: T Baba; P A Convery; N Matsumura; R S Whitaker; E Kondoh; T Perry; Z Huang; R C Bentley; S Mori; S Fujii; J R Marks; A Berchuck; S K Murphy Journal: Oncogene Date: 2008-10-06 Impact factor: 9.867
Authors: Venkata Lokesh Battula; Yuexi Shi; Kurt W Evans; Rui-Yu Wang; Erika L Spaeth; Rodrigo O Jacamo; Rudy Guerra; Aysegul A Sahin; Frank C Marini; Gabriel Hortobagyi; Sendurai A Mani; Michael Andreeff Journal: J Clin Invest Date: 2012-05-15 Impact factor: 14.808
Authors: Chiara Agnoletto; Fabio Corrà; Linda Minotti; Federica Baldassari; Francesca Crudele; William Joseph James Cook; Gianpiero Di Leva; Adamo Pio d'Adamo; Paolo Gasparini; Stefano Volinia Journal: Cancers (Basel) Date: 2019-04-05 Impact factor: 6.639
Authors: Khalid Abubaker; Ardian Latifi; Rod Luwor; Simon Nazaretian; Hongjian Zhu; Michael A Quinn; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed Journal: Mol Cancer Date: 2013-03-27 Impact factor: 27.401